Bumper Offer - Urjas oil Just @ Rs. 1
Sucral Suspension is a commercial drug that is prescribed in the form of Suspension. It is typically used for the treatment of Peptic Ulcer. Sucral Suspension also has some secondary and off-label uses. These are listed below.
The right dosage of Sucral Suspension depends on the age, gender, and medical history of the patient. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. This information has been provided in detail in the dosage section.
Sucral Suspension also has some side effects, the most common being Constipation. Besides the aforementioned side effects, there are other adverse effects of Sucral Suspension as well, which are listed below. Usually, these side effects of Sucral Suspension go away soon, and do not persist beyond the duration of the treatment. Consult your doctor if these side effects become worse or stay for a longer duration.
Furthermore, you should know that effect of Sucral Suspension is Unknown for pregnant women and Unknown for women who are breastfeeding. In addition, Sucral Suspension's effects on the liver, heart and kidney are discussed below in the Sucral Suspension related warnings section.
Sucral Suspension is not recommended if you suffer from certain medical conditions as it can have adverse effects. Diabetes are examples of such conditions. Some other conditions that can be affected by Sucral Suspension are listed in the contraindications section below.
Drug reaction of Sucral Suspension with other medicines has been reported. A complete list of these interactions is given below.
Along with the above-mentioned precautions, remember that taking Sucral Suspension is considered not safe while driving, and is not addictive.
Sucral Suspension is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
Based on research, the following side effects have been observed when Sucral Suspension is used -
Moderate
Mild
Common
Is the use of Sucral Suspension safe for pregnant women?
The effects of Sucral on pregnant women are unknown since no research has been done to ascertain it yet.
Is the use of Sucral Suspension safe during breastfeeding?
Information about safety of Sucral for women who are breastfeeding is not available since scientific research on this is yet to be done.
What is the effect of Sucral Suspension on the Kidneys?
Sucral rarely harms the kidneys.
What is the effect of Sucral Suspension on the Liver?
Sucral does not damage the liver.
What is the effect of Sucral Suspension on the Heart?
You can take Sucral without any fear of damage to the heart.
Sucral Suspension should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Sucral Suspension unless your doctor advises you to do so -
Is this Sucral Suspension habit forming or addictive?
Sucral Suspension is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
After taking Sucral Suspension you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
Sucral Suspension is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
There is no benefit of taking Sucral Suspension for mental disorders.
Interaction between Food and Sucral Suspension
It is safe to take Sucral Suspension with food.
Interaction between Alcohol and Sucral Suspension
Information about the interaction of Sucral Suspension and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155